Results reported by
- Amylyx Pharmaceuticals
Amylyx reported that once-daily avexitide reduced the composite rate of Level 2 and Level 3 hypoglycemic events by 55% versus placebo in the Phase 3 LUCIDITY trial. The company announcement is topline evidence; ClinicalTrials.gov lists NCT06747468 with no results posted.
What happened
- Amylyx announced topline results from a randomized, double-blind, placebo-controlled Phase 3 study in post-bariatric hypoglycemia.
- The company reported a 55% reduction in the prespecified composite event rate versus placebo and said all secondary endpoints were met.
Why it matters
A positive pivotal readout could support the company's planned regulatory submission for a condition with no approved pharmacologic treatment.
Key details
- Trial
- NCT06747468
- Evidence status
- Company-reported topline results; no results posted in the registry
- Enrollment
- 78 participants reported by Amylyx
What to watch
- Full arm-level event rates, confidence intervals, participant flow, component effect sizes, and complete safety tables.
Event chronology
How the story developed
Topline results announced
Amylyx released company-reported Phase 3 LUCIDITY topline results.
Evidence ledger
Sources behind this brief
- 01Primary source
Amylyx LUCIDITY topline announcement
company reported result · Accessed August 24, 2026
- 02